Eli Rosenbaum

BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

Mingzhao Xing, William H. Westra, Ralph P. Tufano et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 986 citations · Full text

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad et al. · The Lancet Oncology · 2019 · 383 citations · Full text

Era 223, Urology, Medicine +8

Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection

Mohammad Obaidul Hoque, Shahnaz Begum, Özlem Topaloglu et al. · JNCI Journal of the National Cancer Institute · 2006 · 261 citations

Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer

Mingzhao Xing, Ralph P. Tufano, Anthony P. Tufaro et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 257 citations · Full text